Clincosm LogoSign in Get a demo

Transcriptomic Study of IBD-associated Colorectal Cancer

Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Completed
CT.gov ID
NCT05060770
Collaborator
(none)
26
Enrollment
132
Actual Duration (Months)

Study Details

Study Description

Brief Summary

Chronic inflammatory bowel disease (IBD) is associated with an increased risk of colorectal cancer (CRC) in historical cohorts. The pathways of oncogenesis of these CRCs, which are very different clinically from de novo CRCs, are currently unknown. The aim of our work is to identify specific molecular signatures of CRC occurring in the setting of IBD.

Condition or Disease Intervention/Treatment Phase
  • Genetic: transcriptomic analysis

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
26 participants
Observational Model:
Case-Only
Time Perspective:
Other
Official Title:
Transcriptiomic Analysis of Inflammatory Bowel Disease-associated Colorectal Cancer. A French Retrospective Study of 26 Cases Identified at the Nancy University Hospital
Actual Study Start Date :
Jan 1, 2010
Actual Primary Completion Date :
Jan 1, 2021
Actual Study Completion Date :
Jan 1, 2021

Outcome Measures

Primary Outcome Measures

  1. IBD associated CRC oncogenesis [1 year]

    Percentage of gene expression variation in CRC tumor tissue samples in the following groups patients with CRC and IBD

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Inclusion Criteria:

  • Person 18 years of age or older

  • Person with colorectal cancer in the context of IBD

  • Person who has received complete information on the organization of the research and who has signed an informed consent

  • Person affiliated to a social security plan or beneficiary of such a plan.

Exclusion Criteria:

  • Person referred to in articles L. 1121-5, L. 1121-7 and L1121-8 of the public health code:

  • Pregnant woman, parturient or nursing mother

  • Minor (not emancipated)

  • Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)

  • Person of legal age who is unable to express his or her consent

  • Person deprived of liberty by a judicial or administrative decision, persons subject to psychiatric care under articles L. 3212-1 and L. 3213-1.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Central Hospital, Nancy, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
MULLER Marie, Doctor (MD, PhD Student), Principal investigator, Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT05060770
Other Study ID Numbers:
  • 2021PI125
First Posted:
Sep 29, 2021
Last Update Posted:
Oct 7, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by MULLER Marie, Doctor (MD, PhD Student), Principal investigator, Central Hospital, Nancy, France
inflammatory bowel disease
Additional relevant MeSH terms:
Colorectal Neoplasms
Inflammatory Bowel Diseases

Study Results

No Results Posted as of Oct 7, 2021